TY - JOUR AU - Wang, Chunguo AU - Xu, Feng AU - Shen, Jianfei AU - Zhang, Linna AU - Zhang, Jian AU - Jin, Jiang AU - Ampollini, Luca AU - Schil, Paul van AU - Kimura, Hideharu AU - Grossi, Francesco AU - Suda, Kenichi AU - Zhang, Bo AU - Ma, Dehua AU - AME Lung Cancer Collaborative Group, written on behalf of the PY - 2018 TI - Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification JF - Journal of Thoracic Disease; Vol 10, No 11 (November 28, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - In the past, the optimal first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with wild-type for epidermal growth factor receptor (wt-EGFR) has been platinum-based chemotherapy doublets (1,2). More recently, clinicians have adopted immunotherapy with check-point inhibitors alone, in PD-L1 strong positive, or combined with chemotherapy independently to PD-L1 expression (3). UR - https://jtd.amegroups.org/article/view/24888